Pancreatic Cancer

被引：2282
作者：
Hidalgo, Manuel [1 ,2 ,3 ]
机构：
[1] Ctr Nacl Invest Oncol, Madrid, Spain
[2] Hosp Madrid, Madrid, Spain
[3] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2010年 / 362卷 / 17期
关键词：
PHASE-III TRIAL; RANDOMIZED CONTROLLED-TRIAL; DUCTAL ADENOCARCINOMA; CURATIVE-INTENT; TUMOR-GROWTH; RISK-FACTORS; ADJUVANT CHEMOTHERAPY; PLUS CAPECITABINE; CLINICAL BENEFIT; STELLATE CELLS;
D O I：
10.1056/NEJMra0901557
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Deaths from pancreatic ductal adenocarcinoma, also known as pancreatic cancer, rank fourth among cancer-related deaths in the United States, yet the causes of pancreatic cancer remain unknown. This review article summarizes recent progress in the understanding and management of pancreatic cancer. Copyright © 2010 Massachusetts Medical Society.
引用
收藏
页码：1605 / 1617
页数：13
相关论文
共 89 条
  • [1] Both p16Ink4a and the p19Arf-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse
    Bardeesy, N
    Aguirre, AJ
    Chu, GC
    Cheng, KH
    Lopez, LV
    Hezel, AF
    Feng, B
    Brennan, C
    Weissleder, R
    Mahmood, U
    Hanahan, D
    Redston, MS
    Chin, L
    DePinho, RA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (15) : 5947 - 5952
  • [2] Risk Factors for Pancreatic Cancer Mortality: Extended Follow-up of the Original Whitehall Study
    Batty, G. David
    Kivimaki, Mika
    Morrison, David
    Huxley, Rachel
    Smith, George Davey
    Clarke, Robert
    Marmot, Michael G.
    Shipley, Martin J.
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2009, 18 (02) : 673 - 675
  • [3] Postresection CA 19-9 Predicts Overall Survival in Patients With Pancreatic Cancer Treated With Adjuvant Chemoradiation: A Prospective Validation by RTOG 9704
    Berger, Adam C.
    Garcia, Miguel, Jr.
    Hoffman, John P.
    Regine, William F.
    Abrams, Ross A.
    Safran, Howard
    Konski, Andre
    Benson, Alan B., III
    MacDonald, John
    Willett, Christopher G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (36) : 5918 - 5922
  • [4] Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone:: A randomized multicenter phase III clinical trial -: SAKK 44/00-CECOG/PAN.1.3.001
    Bernhard, Juerg
    Dietrich, Daniel
    Scheithauer, Werner
    Gerber, Daniela
    Bodoky, Gyo Rgy
    Ruhstaller, Thomas
    Glimelius, Bengt
    Bajetta, Emilio
    Schueller, Johannes
    Saletti, Piercarlo
    Bauer, Jean
    Figer, Arie
    Pestalozzi, Bernhard C.
    Hne, Claus-Henning Ko
    Mingrone, Walter
    Stemmer, Salomon M.
    Tamas, Karin
    Kornek, Gabriela V.
    Koeberle, Dieter
    Herrmann, Richard
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) : 3695 - 3701
  • [5] Validation of the 6th Edition AJCC Pancreatic Cancer Staging System - Report from the National Cancer Database
    Bilimoria, Karl Y.
    Bentrem, David J.
    Ko, Clifford Y.
    Ritchey, Jamie
    Stewart, Andrew K.
    Winchester, David P.
    Talamonti, Mark S.
    [J]. CANCER, 2007, 110 (04) : 738 - 744
  • [6] Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
    Burris, HA
    Moore, MJ
    Andersen, J
    Green, MR
    Rothenberg, ML
    Madiano, MR
    Cripps, MC
    Portenoy, RK
    Storniolo, AM
    Tarassoff, P
    Nelson, R
    Dorr, FA
    Stephens, CD
    VanHoff, DD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) : 2403 - 2413
  • [7] Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer.: Definitive results of the 2000-01 FFCD/SFRO study
    Chauffert, B.
    Mornex, F.
    Bonnetain, F.
    Rougier, P.
    Mariette, C.
    Bouche, O.
    Bosset, J. F.
    Aparicio, T.
    Mineur, L.
    Azzedine, A.
    Hammel, P.
    Butel, J.
    Stremsdoerfer, N.
    Maingon, P.
    Bedenne, L.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 (09) : 1592 - 1599
  • [8] Stromal biology of pancreatic cancer
    Chu, Gerald C.
    Kimmelman, Alec C.
    Hezel, Aram F.
    DePinho, Ronald A.
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 2007, 101 (04) : 887 - 907
  • [9] In vitro and In vivo Radiosensitization with AZD6244 (ARRY-142886), an Inhibitor of Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase 1/2 Kinase
    Chung, Eun Joo
    Brown, Aaron P.
    Asano, Hiroaki
    Mandler, Mariana
    Burgan, William E.
    Carter, Donna
    Camphausen, Kevin
    Citrin, Deborah
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (09) : 3050 - 3057
  • [10] The prevalence of BRCA2 mutations in familial pancreatic cancer
    Couch, Fergus J.
    Johnson, Michele R.
    Rabe, Kari G.
    Brune, Kieran
    de Andrade, Mariza
    Goggins, Michael
    Rothenmund, Heidi
    Gallinger, Steven
    Klein, Alison
    Petersen, Gloria M.
    Hruban, Ralph H.
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2007, 16 (02) : 342 - 346
123456789